
microRNAs in Toxicology and Medicine






microRNAs in Toxicology and Medicine

Editor

SAURA C. SAHU

Division of Toxicology, Center for Food Safety and Applied Nutrition, Food and Drug Administration, USA





This edition first published 2014 © 2014 John Wiley, & Sons, Ltd.

Registered office

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, United Kingdom

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com.

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. It is sold on the understanding that the publisher is not engaged in rendering professional services and neither the publisher nor the author shall be liable for damages arising herefrom. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

microRNAs in Toxicology and Medicine / editor, Saura C. Sahu.
pages cm
Includes bibliographical references and index.
ISBN 978-1-118-40161-3 (cloth)

1. Small interfering RNA. 2. Small interfering RNA - Therapeutic use. 3. Genetic regulation. I. Sahu,

Saura C., editor of compilation. QP623.5.S63M536 2014

572.8'8 - dc23

2013020036

A catalogue record for this book is available from the British Library,

ISBN: 9781118401613

Set in 10/12pt Times by Laserwords Private Limited, Chennai, India

Printed and bound in Singapore by Markono Print Media Pte Ltd

microRNAs in Toxicology and Medicine

I lovingly dedicate this book to:

My parents, Gopinath and Ichhamoni, for their gifts of life, love and living examples

My wife, Jharana, for her life-long friendship, love and support, as well as for her patience and understanding of the long hours spent at home on planning, writing and editing this book.

My children, Megha, Sudhir and Subir, for their love and care

Saura C. Sahu Laurel, Maryland, USA

List of Contributors

- Aamir Ahmad Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, USA
- Malin Åkerblom Department of Experimental Medical Science, Wallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, Sweden
- Nahid Akhtar Department of Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), USA
- Azfur S. Ali Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, USA
- Shadan Ali Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, USA
- Sumit Arora Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, USA
- **Kathryn A. Bailey** Department of Environmental Sciences and Engineering, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA
- **Arun Bhardwaj** Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, USA
- **Barbara Burwinkel** Molecular Epidemiology C080, German Cancer Research Center, Germany *and* Molecular Biology of Breast Cancer, University Women's Clinic, Germany
- Si Chen Division of Biochemical Toxicology, National Center for Toxicological Research/US Food and Drug Administration, USA
- **Tao Chen** Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, Food and Drug Administration, USA
- Sang-Woon Choi Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, USA and Friedman School of Nutrition Science and Policy, Tufts University, USA
- Pierre Cordelier INSERM U1037, Cancer Research Center of Toulouse, France and Université Paul Sabatier Toulouse III. France
- Katarina Cuk Molecular Epidemiology C080, German Cancer Research Center, Germany and Molecular Biology of Breast Cancer, University Women's Clinic, Germany
- Yang Dai Department of Bioengineering, University of Illinois at Chicago, USA
- Christopher J. Davis WWAMI Medical Education Program and Program in Neuroscience, Sleep and Performance Research Center, Washington State University, USA
- Joel Fontanarosa Department of Bioengineering, University of Illinois at Chicago, USA
- Jennifer L. Freeman School of Health Sciences, Purdue University, USA
- Simonetta Friso University of Verona School of Medicine, Italy
- **Rebecca C. Fry** Department of Environmental Sciences and Engineering, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA
- Luc Gailhouste Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Japan

Marion Gayral INSERM U1037, Cancer Research Center of Toulouse, France and Université Paul Sabatier Toulouse III, France

Samir N. Ghadiali The Ohio State University, Dorothy M. Davis Heart and Lung Research Institute, USA Lei Guo Division of Biochemical Toxicology, National Center for Toxicological Research/US Food and Drug Administration, USA

Keitaro Hagiwara Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Japan and Department of Biological Sciences, Tokyo Institute of Technology, Japan

Tariq M. Haqqi Department of Anatomy and Neurobiology, Northeast Ohio Medical University (NEOMED), USA

Valerie W. Hu Department of Biochemistry and Molecular Medicine, The George Washington University School of Medicine and Health Sciences, USA

Yan Huang The Ohio State University, Dorothy M. Davis Heart and Lung Research Institute, USA Brock Humphries Department of Physiology, Michigan State University, USA

Johan Jakobsson Department of Experimental Medical Science, Wallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, Sweden

Matthias Jung Clinic for Psychiatry, Psychotherapy, and Psychosomatic medicine, Martin Luther University, Germany

Daniel B. Kay Department of Psychiatry and Human Behavior University of Mississippi Medical Center, School of Medicine, USA

Nobuyoshi Kosaka Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Japan

Zhenhua Liu School of Public Health and Health Sciences, University of Massachusetts, USA and Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, USA

Yang Luan School of Public Health, Shanghai Jiao Tong University, China

Dharanija Madhavan Molecular Epidemiology C080, German Cancer Research Center, Germany and Molecular Biology of Breast Cancer, University Women's Clinic, Germany

Josephine Malmevik Department of Experimental Medical Science, Wallenberg Neuroscience Center and Lund Stem Cell Center, Lund University, Sweden

William B. Mattes PharmPoint Consulting, USA

Fanxue Meng Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, Food and Drug Administration, USA

S. Patrick Nana-Sinkam The Ohio State University, Dorothy M. Davis Heart and Lung Research Institute, USA

Takahiro Ochiya Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Japan

Philip A. Philip Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, USA

Barry A. Rosenzweig Division of Drug Safety Research, Center for Drug Evaluation and Research, US Food and Drug Administration, USA

Rodney L. Rouse Division of Drug Safety Research, Center for Drug Evaluation and Research, US Food and Drug Administration, USA

Saura C. Sahu Division of Toxicology, Center for Food Safety and Applied Nutrition, Food and Drug Administration, USA

William F. Salminen PAREXEL, USA

Tewarit Sarachana Department of Biochemistry and Molecular Medicine, The George Washington University School of Medicine and Health Sciences, USA

Fazlul H. Sarkar Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, USA and Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, USA

Insa S. Schroeder Department of Biophysics, GSI Helmholtz Centre for Heavy Ion Research, Germany Maria S. Sepúlveda Department of Forestry and Natural Resources, Purdue University, USA

Leming Shi School of Pharmacy, Fudan University, China

Qiang Shi Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, USA

Ajay P. Singh Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, USA and Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, USA

Seema Singh Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama,

Geir Skogerbø National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, China

Stephanie A. Tammen Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, USA and Friedman School of Nutrition Science and Policy, Tufts University, USA

Karol L. Thompson Division of Drug Safety Research, Center for Drug Evaluation and Research, US Food and Drug Administration, USA

Jérome Torrisani INSERM U1037, Cancer Research Center of Toulouse, France and Université Paul Sabatier Toulouse III, France

Andrey Turchinovich Molecular Epidemiology C080, German Cancer Research Center, Germany and Molecular Biology of Breast Cancer, University Women's Clinic, Germany

Zhishan Wang Department of Physiology, Michigan State University, USA

Gregory J. Weber School of Health Sciences, Purdue University, USA

Zuquan Weng Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, USA

Yaguang Xi Mitchell Cancer Institute, University of South Alabama, USA

Jiekun Xuan Division of Biochemical Toxicology, National Center for Toxicological Research/US Food and Drug Administration, USA

Dongsheng Yan School of Ophthalmology and Optometry, Wenzhou Medical College, China

Jian Yan Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, Food and Drug Administration, USA

Chengfeng Yang Department of Physiology, Michigan State University, USA and Center for Integrative Toxicology, Michigan State University, USA

Xi Yang Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, USA

Bin Yi Mitchell Cancer Institute, University of South Alabama, USA

Preface

During the past decade it has become increasingly obvious that microRNAs regulate gene expressions and control many developmental and cellular processes in the eukaryotic organisms. Recent studies strongly suggest that they are likely to play important roles in a wide range of human diseases including cancer. As a result they have become an important component of the molecular mechanisms of the disease processes. Also, published reports strongly suggest that they are expected to play important roles in cellular response to xenobiotic stress affecting expression of microRNA as a mechanism of adaptation and, therefore, they have attracted great interest in toxicology. Thus microRNAs play an important role in toxicogenomics.

The importance of this field of research is evidenced by the increasing number of contributions published each year. It becomes increasingly clear that developments in this field are moving so rapidly that new means are needed to report the status of current ongoing research activities. The contributions presented in this monograph represent a collaborative effort by international experts working in this emerging field of science.

The main purpose of this book is to assemble up-to-date, state-of-the-art information on microRNAs presented by internationally recognized experts in a single edition. Therefore, I sincerely hope that this book will provide an authoritative source of current information on microRNA research and prove useful to the scientists interested in this scientific discipline throughout the world. It is my sincere hope that the information presented in this book will serve as a stimulus to all the investigators interested in this area of research. Also it should be of interest to a variety of other scientific disciplines including toxicology, medicine, and pharmacology, as well as food, drug, and other regulatory sciences.

Saura C. Sahu Laurel, Maryland, USA

Acknowledgments

Editing this book has been a challenging journey. I express my sincere gratitude to all the individuals who have helped me, directly or indirectly, on this journey.

I am indebted to the internationally recognized experts, who shared my enthusiasm for this field of science and contributed generously to this book. They were selected from academia, industry, and government for their expertise in their own areas of research. Their work speaks for itself and I am grateful to them for their strong commitment, cooperation and excellent contributions in their own areas of expertise.

I thank the staff of the publisher, John Wiley & Sons, Ltd, especially Rebecca Ralf and Sarah Tilley for their excellent help, cooperation, support, and editorial assistance in the timely publication of this book.

Saura C. Sahu Laurel, Maryland, USA

Contents

Lis	t of Co	ntributor.	S	XVII
Pre	eface			xxi
Aci	knowled	dgments		xxiii
PA	RT I	microR	NAs AND TOXICOLOGY	1
1		duction a C. Sahi		3
	Refer			4
2			al Toxicants and Perturbation of miRNA Signaling	5
		-	ailey and Rebecca C. Fry	-
	2.1	Introduc		5 8
	2.2	2.2.1	s: Description and Biological Significance miRNA Biosynthesis and Processing	8
		2.2.1	Interaction of miRNAs with mRNA Targets	9
	2.3		nmental Toxicant-Associated miRNA Perturbations	10
	2.5	2.3.1	Toxicant Class 1: Carcinogenic Metals (Arsenic and Cadmium)	10
		2.3.2	Toxicant Class 2: Air Toxicants (Formaldehyde, Diesel Exhaust Particles,	
			Cigarette Smoke)	13
		2.3.3	Toxicant Class 3: Polycyclic Aromatic Hydrocarbon $(B(a)P)$	17
		2.3.4	Toxicant Class 4: Endocrine Disruptors (BPA, DDT, Fludioxonil, Fenhexamid,	
			and Nonylphenol)	19
	2.4	Conclus	sions and Future Directions	22
	Ackn	owledgm	ents	22
	Refer	rences	· ·	22
3	micro	oRNAs in	n Drug-Induced Liver Toxicity	33
			un Xuan and Lei Guo	
	3.1	Introdu		33
	3.2		Tissue Distribution and Abundance	34
		3.2.1	miRNA in Solid Tissues	34
	2.2	3.2.2	microRNA in Body Fluids	35
	3.3		and Drug-Induced Liver Toxicity	35
		3.3.1	Acetaminophen	36

		3.3.2 Carbon Tetrachloride (CCl ₄)	37
		3.3.3 2,3,7,8-Tetrachlorodibenzo- <i>p</i> -Dioxin (TCDD)	37
		3.3.4 Benzo[a]pyrene	37
		3.3.5 Tamoxifen	38
		3.3.6 Others	38
	3.4	Circulating miRNAs as Potential Biomarkers for Drug-Induced Liver Toxicity	38
		3.4.1 Introduction of Circulating miRNAs	38
		3.4.2 Blood miRNAs in Drug-Induced Liver Toxicity	39
		3.4.3 Urine miRNAs in Drug-Induced Liver Toxicity	41
		3.4.4 Technique Challenges	42
	3.5	Mechanistic Studies and Perspectives	42
	Discla	iimer	44
	Refer	ences	44
4	Fishi	ng for microRNAs in Toxicology	49
	Jenni	fer L. Freeman, Gregory J. Weber and Maria S. Sepúlveda	
	4.1	microRNAs in Toxicology	49
	4.2	Fish Models in Toxicology	49
		4.2.1 Small Fish Models in Toxicology	50
		4.2.2 Large Fish Models in Toxicology	51
	4.3	Fish as Models for Studying miRNA Function	51
		4.3.1 miRNA Studies in Zebrafish	51
		4.3.2 miRNA Studies in Other Fish Models	52
	4.4	Application of Fish Models in Toxicity Studies of miRNA Alterations	52
		4.4.1 Zebrafish in Toxicity Studies of miRNA Alterations	52
		4.4.2 Other Fish Models in Toxicity Studies of miRNA Alterations	68
	4.5	Summary	68
		owledgments	68
	Refer	ences	68
PA	RT II	microRNAs AND DISEASE STATES	77
5	micro	RNAs and Inflammation	79
		Iuang, Samir N. Ghadiali and S. Patrick Nana-Sinkam	
	5.1	Introduction	79
	5.2	miRNA Biogenesis and Functions	80
	5.3	miRNAs in Hematopoietic Systems	80
	5.4	miRNA and Inflammatory Diseases	81
	5.5	Regulation of the Immune System	86
		5.5.1 Acquired Immunity	86
	E 2	5.5.2 Innate Immunity	86
	5.6	Regulation of miRNA Expression	87
		5.6.1 Regulation of miRNA by Cytokines and Bacterial Toxins	87
		5.6.2 Regulation of miRNA by Mechanical Stimuli	88
	5.7	Select miRNA Regulation of Inflammation	89

				Contents	ix
		5.7.1	miR-146a: Negative Regulator of Immune Response		89
		5.7.2	Role of miR-155 in Mediating Inflammatory Responses		91
		5.7.3	miR-125a/b		92
		5.7.4	miR-181a		93
	5.8	Conclu	sion		94
	Refei	rences			94
6	Regu	ılatory R	Role of microRNAs in Mutagenesis		101
	Fanx	ue Meng	g, Yang Luan, Jian Yan and Tao Chen		
	6.1	Introdu	ction		101
	6.2		A Roles in Xenobiotic Metabolism		102
	6.3	miRNA	A Roles in the Cell Cycle		105
	6.4		A Roles in DNA Repair		106
	6.5	Apopto			107
	6.6		A Regulation and Mutation Formation		108
	6.7	Conclu	sions		109
		aimer			109
	Refe	rences			110
7	microRNAs and Cancer				113
			an and Geir Skogerbø		
	7.1	Introdu			113
	7.2		As are Deregulated in Cancer		114
	7.3		As Function as Oncogenes and Tumor Suppressor Genes		116
	7.4		As in Cancer Metastasis		117
	7.5		As in Cancer Stem Cells		119 119
	7.6		ons in miRNA Loci		120
	7.7		ons in miRNA Target Genes		120
	7.8	Prospe nowledgn	ctive: miRNA as Biomarkers and Therapeutics		121
		rences	itents		121
0	270	NT 4			133
8			Cancer Invasion and Metastasis		133
	8.1	Introdu	hries and Chengfeng Yang		133
	8.2		As and Cancer Invasion and Metastasis		136
	0.2	8.2.1	miRNAs Involved in Angiogenesis		136
		8.2.2	miRNAs Involved in Angiogenesis miRNAs Involved in Cancer Cell Detachment, Migration, and Invasion		138
		8.2.3	miRNAs Involved in Cancer Cell Intravasation		140
		8.2.4	miRNAs Involved in Circulating Cancer Cell Survival		142
		8.2.5	miRNAs Involved in Cancer Cell Extravasation		143
		8.2.6	miRNAs Involved in Metastatic Colonization		144
	8.3		As as Useful Cancer Prognostic Markers		146
	8.4		Perspectives		147
	References				148

9		Role of microRNAs in Tumor Progression and Therapy	153
	Azfur	r S. Ali, Aamir Ahmad, Shadan Ali, Philip A. Philip and Fazlul H. Sarkar	
	9.1	Introduction	153
	9.2	Tumor Progression	154
	9.3	Key Signaling Pathways	154
		9.3.1 Angiogenesis	154
		9.3.2 The Ras Pathway	155
		9.3.3 The Epidermal Growth Factor Receptor Pathway	155
		9.3.4 The PI3K/Akt Pathway	156
	9.4	The miRNAs as Regulators of Tumor Progression	156
		9.4.1 Current Therapies to Control Tumor Progression	157
		9.4.2 Tumor Promoter miRNAs	158
		9.4.3 Tumor Suppressor miRNAs	159
	9.5	Regulation of miRNAs by Novel Anticancer Compounds	160
	9.6	Conclusions and Perspectives	161
	Refer	rences	162
10		rent Understanding of microRNAs as Therapeutic Targets in Cancer	167
		on Gayral, Jérome Torrisani and Pierre Cordelier	1.65
	10.1	Introduction on the Rationale of Using miRNAs as Therapeutics in Cancer	167
	10.2		167
	10.3		168
	10.4		170
	10.5	e e	170
	Refer	rences	170
11		oRNAs, New Players in Cancer Chemoprevention	173
		Yi and Yaguang Xi	
	11.1		17.
	11.2		17:
		11.2.1 Vitamin A	17:
		11.2.2 Vitamin B	170
8		11.2.3 Vitamin D	170
		11.2.4 Vitamin E	170
		11.2.5 Fatty Acids	170
		11.2.6 Curcumin	17
		11.2.7 Resveratrol	173
		11.2.8 Ellagitannin	17
		11.2.9 Genistein	17
		11.2.10 Catechins	173
	a 100	11.2.11 Indoles	173
	11.3	miRNA and Pharmaceuticals	173
		11.3.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	173
		11.3.2 Estrogen Receptor Antagonist	18

				Contents >	κi
	11.4	Perspec	etives	18	2
	Ackno	owledgm	nents	18.	3
	Refer	ences		18	3
12	micro	RNA an	nd Neurodegenerative Diseases	18	9
			ulmevik, Malin Åkerblom and Johan Jakobsson		
		Introduc		18	9
	12.2	miRNA	as and Parkinson's Disease	19	1
	12.3	miRNA	as and Alzheimer's Disease	19	3
	12.4	miRNA	as and Huntington's Disease	19.	5
	12.5	Outlook	k	19.	5
	Ackno	owledgm	nents	19	6
	Refer	ences		19	6
13	Sleep	and mic	croRNAs (miRNAs) in Neurodegenerative Diseases	20	1
			y and Christopher J. Davis		
	13.1	-	and microRNAs (miRNAs) in Neurodegenerative Diseases	20	1
	13.2	miRNA	as and Sleep	20	2
	13.3	Aging	•	20	3
	13.4	Alzhein	ner's Disease	20	4
	13.5	Parkins	son's Disease	20	5
	13.6	Creutzf	feldt–Jakob Disease	20	6
	13.7	Hunting	gton's Disease	20	7
	13.8	Multipl	e Sclerosis	20	8
	13.9	Fronto-	Temporal Dementia	20	8
	13.10	Summa	ury	20	8
	Ackno	owledgm	nents	20	9
	Refer	ences		20	9
14	Role	of micro	pRNAs in Autism Spectrum Disorder	21	5
	Tewar	rit Sarac	hana and Valerie W. Hu		
	14.1	Introdu	ction	21	5
	14.2	Epidem	niology of ASD	21	6
	14.3	Etiolog	y of ASD: Genetic Associations	21	6
	14.4	ASD as	s Multigenic Systemic Disorders	21	7
	14.5	Evidend	ce for Epigenetic Contributions	21	8
	14.6	The Ro	ole of microRNAs in Neurodevelopment	21	8
	14.7		NAs in Neurodevelopmental and Psychiatric Disorders: An Overview	21	
	14.8	microR	NA Expression Profiles in Autism Spectrum Disorder	22	
		14.8.1	Evidence for Dysregulated miRNAs in Brain and Blood	22	0
		14.8.2	Identification of Novel Gene Targets of Differentially Expressed miRNAs		
			ASD	22	0
		14.8.3	Brain-Related miRNAs are Differentially Expressed in LCLs from Individ		_
			with ASD	22	2

		14.8.4 Functional Associations of Confirmed Differentially Expressed miRNAs Conclusions	225 226		
		owledgments ences	227 227		
15	The Emerging Function of Natural Products as Regulators of miRNAs in Human				
	Disea		237		
		ro Hagiwara, Luc Gailhouste, Nobuyoshi Kosaka and Takahiro Ochiya			
	15.1	Introduction	237		
	15.2	History of Natural Products as Drugs	238		
	15.3	Functions of miRNAs in Human Diseases	238		
	15.4 15.5	Regulation of miRNAs using Natural Products	239		
	15.5	Resveratrol and miRNAs EGCG and miRNAs	239		
	15.7		241 242		
	15.8		242		
		Metformin miRNA	242		
		Traditional Herbs and miRNAs	243		
		Polyphenol and miRNAs	243		
		Rice and miRNA	243		
	15.13	Human Breast Milk and miRNAs	244		
	15.14	Conclusion	245		
	Ackn	owledgments	245		
	Refer	ences	245		
PA	RT III	microRNAs AND STEM CELLS	249		
16		potency and Early Cell Fate Decisions are Orchestrated by microRNAs	251		
		nias Jung and Insa S. Schroeder			
	16.1	The state of the s	251		
	16.2	Biogenesis and Function of microRNAs	252		
	16.3	microRNAs Mark ES Cell Identity	254		
		16.3.1 ES Cell Identity is Characterized by Distinct miRs16.3.2 Mouse ES Cell-Specific miRs	254		
		16.3.3 Human ES Cell-Specific miRs	254 255		
		16.3.4 Self-Renewal of ES Cells is Regulated by Cell Cycle Regulating miRs	255		
		16.3.5 Differentiation Capacity of ES Cells is Maintained by miRs	256		
		16.3.6 Isoforms and 3' Variability in ES Cell-Specific miRs	256		
	16.4	microRNAs Guide Induced Pluripotency	257		
		16.4.1 Reprogramming Factors Regulate ES Cell-Associated miRs	257		
		16.4.2 Differentiation of ES and iPS Cells is Prevented by miRs	258		
		16.4.3 Reprogramming Requires ES Cell-Specific miRs	258		
	16.5	microRNAs Manipulate Cell Fate Decisions	259		
		16.5.1 Induction of Early Differentiation is Regulated by miRs	259		
		16.5.2 Major Signaling Pathways in ES Cells Regulated by miRs	260		
		16.5.3 Differentiation of ES Cells Can be Manipulated by miRs	260		

	Conte	ents xiii
	16.5.4 Cell Fate Decisions are Influenced by miRs and RNA Binding	
	Proteins (RBPs)	261
	References	262
17	microRNAs in Cancer Stem Cells: Micromanagers of Malignancy	269
**	Arun Bhardwaj, Sumit Arora, Seema Singh, and Ajay P. Singh	-
	17.1 Introduction	269
	17.2 Cancer Stem Cells	270
	17.2.1 Origin of Cancer Stem Cells	270
	17.2.2 Characteristics and Pathological Significance of Cancer Stem Cells	271
	17.3 microRNAs: Biology and Mechanism	273
	17.4 Role of microRNAs in the Regulation of Genes and Signaling Pathways Associated	
	with Cancer Stem Cells	273
	17.4.1 HMGA2	275
	17.4.2 Bcl-2	275
	17.4.3 Bmi-1	276
	17.4.4 Wnt/β-Catenin	276
	17.4.5 Notch	277
	17.4.6 Hedgehog	277
	17.4.7 TGF-β	278
	17.5 Translational Implications and Future Perspectives	279
	References	279
DA	RT IV microRNAs AND GENOMICS	285
1/1	RT IV IIICIORIVAS AND GENOMICS	200
4.0		207
18	microRNAs: Tiny Regulators of Great Potential for Gene Regulation	287
	Nahid Akhtar and Tariq M. Haqqi	207
	18.1 Introduction	287
	18.2 microRNAs: Biogenesis and Expression Criteria	288
	18.3 Mechanism of miRNA Mediated Regulation of Genes	288
	18.4 Complexities of miRNA Regulation	290 291
	18.5 microRNA and Epigenetics	291
	18.6 Role of miRNAs in Biological Processes	293
	18.7 microRNAs: Association with Disease Pathogenesis	290
	18.8 microRNAs: Another Way to Unravel Disease Pathogenesis	298
	18.9 microRNAs as Novel Therapeutic Targets	299
	18.10 Concluding Remarks	300
	Competing Interests	300
	Conflict of Interest Statement	300
	Acknowledgments	300
	References	300
- Carrier		300
19	1	es 309
	Joel Fontanarosa and Yang Dai	200
	19.1 Introduction	309